On Thursday, PTC Inc (NASDAQ:PTC)’s shares declined -4.15% to $36.23.
PTC Inc (PTC) declared that administration will speak at the Needham Interconnect Conference on Wednesday, August 5th, 2015 at 8:00am ET.
PTC Inc. develops, markets, and supports software products and solutions in the areas of computer-aided design (CAD), product lifecycle administration (PLM), application lifecycle administration (ALM), service lifecycle administration (SLM), and Internet of things (IoT) worldwide.
World Wrestling Entertainment, Inc. (NYSE:WWE)’s shares gained 17.48% to $19.36.
WWE (WWE) declared that SummerSlam will expand from a three-hour show to a four-hour telecast live on WWE Network and now start at 7pm ET on Sunday, August 23. SummerSlam joins WWE’s annual pop-culture extravaganza, WrestleMania®, as the only two events with four hours of live non-stop action.
Emanating live from a sold-out Barclays Center in Brooklyn, NY, SummerSlam will feature WWE Superstars Undertaker® and Brock Lesnar® in a rematch of their historic WrestleMania 30 bout where Lesnar ended Undertaker’s undefeated streak. In addition, WWE Network will also air a one-hour live SummerSlam Kick-Off Show starting at 6pm ET.
World Wrestling Entertainment, Inc., an integrated media and entertainment company, engages in the sports entertainment business in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. The company operates through Network, Television, Home Entertainment, Digital Media, Live Events, Licensing, Venue Merchandise, WWEShop, and WWE Studios segments.
At the end of Thursday’s trade, Halcon Resources Corp (NYSE:HK)‘s shares surged 1.94% to $1.05.
Halcón Resources Corporation (HK) declared its second quarter 2015 results.
The Company produced an average of 41,297 barrels of oil equivalent per day (Boe/d) during the period. Second quarter 2015 production was 80% oil, 9% natural gas liquids (NGLs) and 11% natural gas.
Halcón generated revenues of $168.0 million for the three months ended June 30, 2015. In addition, the Company realized a net gain on settled derivative contracts of $88.1 million during the quarter.
Counting the impact of hedges, Halcón realized 140% of the average NYMEX oil price, 20% of the average NYMEX oil price for NGLs and 113% of the average NYMEX natural gas price during the period.
Total operating costs per unit, after adjusting for selected items (see Selected Operating Data table for additional information), reduced by 28% to $17.51 per Boe in the second quarter of 2015, contrast to the second quarter of 2014.
Halcón Resources Corporation, an independent energy company, is engaged in the acquisition, production, exploration, and development of onshore oil and natural gas properties in the United States.
Exelixis, Inc. (NASDAQ:EXEL), ended its Thursday’s trading session with -1.07% loss, and closed at $5.54.
Exelixis, Inc. (EXEL) declared the appointment of Christopher J. Senner as Executive Vice President and Chief Financial Officer. Mr. Senner has nearly 25 years of experience in biopharmaceutical finance, counting deep expertise in global financial operations and controls, planned planning and analysis, supply chain finance and business development. He joins Exelixis after five years at Gilead Sciences, where he served as Vice President, Corporate Finance. He formerly spent eighteen years at Wyeth in a variety of financial roles with increasing responsibility for many of the company’s divisions and regions. He joins Exelixis in advance of several potentially transformational milestones anticipated this year, counting top-line results from the METEOR phase 3 pivotal trial and the potential U.S. and EU regulatory approvals of cobimetinib, a compound discovered by Exelixis and then licensed to Genentech for further development and commercialization.
In this role, Mr. Senner will oversee the company’s global finance function, leveraging extensive experience gained earlier in his career. While at Gilead, he was accountable for controllership and operational financial planning and analysis, counting research and development, manufacturing, commercial operations, and tax and treasury planning. At Wyeth, he served in a variety of capacities, most notably as CFO of the company’s $10 billion U.S. pharmaceuticals business and the BioPharma Business Unit, a $5 billion global inflammation, oncology and hematology business.
Exelixis, Inc., a biopharmaceutical company, develops and sells small molecule therapies for the treatment of cancer in the United States. The company offers COMETRIQ, an inhibitor of multiple receptor tyrosine kinases for the treatment of patients with progressive, metastatic medullary thyroid cancer. It is also evaluating cabozantinib in various development programs comprising about 45 clinical trials, counting 2 ongoing phase 3 pivotal trials focusing on metastatic renal cell carcinoma (mRCC) and advanced hepatocellular carcinoma (HCC).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
